Latest Belimumab Stories

BENLYSTA(TM) SUCCESSFUL IN FIRST OF TWO PIVOTAL CLINICAL TRIALSWASHINGTON, July 20 /PRNewswire-USNewswire/ -- Today, Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. When the 52-week study concluded, the lupus patients who were treated with BENLYSTA had improvement in overall disease activity without clinically significant flare-ups in one or more isolated organs when compared to patients who...

ROCKVILLE, Maryland July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will host a conference call today at 8:15 AM Eastern to discuss the results from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )Investors may listen to the call by dialing 888-632-5010 or 913-312-0402, passcode 8364417, five to...

ROCKVILLE, Maryland and LONDON, July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that belimumab plus standard of care achieved a clinically and...

ROCKVILLE, Md., July 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal antibody drug raxibacumab (ABthrax(TM)), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease. (Logo:...

ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Senior management will host a conference call to discuss the results on Monday, July...

- Trial conducted by Novartis evaluating safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial to evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination...

- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years of BENLYSTA therapy - - No increase in overall adverse events, serious adverse events, malignancies or serious infections over time - ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- Human Genome...

- First-in-class treatment for inhalation anthrax - ROCKVILLE, Md., May 21 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its human monoclonal antibody drug ABthrax(TM) (raxibacumab) for the treatment of inhalation anthrax. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) The BLA submission includes the results of two...

- First HGS product sales achieved with delivery of ABthrax(TM) to U.S. Strategic National Stockpile - - $177 million in first quarter revenues; cash balance of $397 million as of March 31, up $24 million from year-end 2008 - - Positive results for second Phase 3 trial of Albuferon(R) in chronic hepatitis C; global marketing applications planned in fall 2009 - - Initiation of Syncria(R) Phase 3 program brings $9 million milestone payment from GSK - ROCKVILLE, Md., April 29...

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events across the two Phase 3 trials, versus peginterferon alfa-2a - - Submission of global marketing applications planned in fall 2009 - ROCKVILLE, Md., April 25...